Katherine E. Fleming-Dutra

Centers for Disease Control and Prevention — United States

Immunology and Microbiology · Life Sciences

46h-index10.9kcitations194works33.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Use and Resistance(64), Pneumonia and Respiratory Infections(62), SARS-CoV-2 and COVID-19 Research(34), Respiratory viral infections research(34), Vaccine Coverage and Hesitancy(27)

Publications193 total

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis
The Lancet Regional Health - Americas·2025· 2 citedOpen Access
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season
Vaccine·2025Open Access
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach
Vaccine·2025· 7 citedOpen Access
426. Effectiveness of Updated (2023-2024) Monovalent COVID-19 Vaccines – VISION Network, September 2023-March 2024
Open Forum Infectious Diseases·2025Open Access
A framework for monitoring RSV prevention product effectiveness in the United States
Vaccine·2025· 5 cited
Surrogate Model Evaluation and Building Energy Benchmarking for Commercial Buildings
SSRN Electronic Journal·2025Open Access
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR Morbidity and Mortality Weekly Report·2024· 18 citedOpen Access
Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness
PEDIATRICS·2024· 16 citedOpen Access
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
PEDIATRICS·2024· 27 citedOpen Access
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
The Lancet·2024· 78 cited
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025
MMWR Morbidity and Mortality Weekly Report·2024· 67 citedOpen Access
Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022–August 2023
Open Forum Infectious Diseases·2024· 3 citedOpen Access
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR Morbidity and Mortality Weekly Report·2024· 127 citedOpen Access
Incorrect Administration of Adult RSV Vaccines to Young Children
PEDIATRICS·2024Open Access
Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR Morbidity and Mortality Weekly Report·2024· 28 citedOpen Access
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
MMWR Morbidity and Mortality Weekly Report·2024· 31 citedOpen Access
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
MMWR Morbidity and Mortality Weekly Report·2024· 73 citedOpen Access
Administration of the GSK Respiratory Syncytial Virus Vaccine to Pregnant Persons in Error
Obstetrics and Gynecology·2024· 3 cited
Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024
MMWR Morbidity and Mortality Weekly Report·2024· 160 citedOpen Access
Development of COVID-19 vaccine policy — United States, 2020–2023
Vaccine·2023· 18 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Lauri A. Hicks(14), Ruth Link‐Gelles(12), Adam L. Hersh(9), Amadea Britton(9), Daniel J. Shapiro(7), Zachary Smith(7), Stephanie J. Schrag(7), Jennifer R. Verani(7), Lauren E. Roper(7), Monica Godfrey(7), Laura Conklin(7), Cynthia G. Whitney(7), Emma K. Accorsi(6), Nong Shang(6), Gordana Derado(6), Oliver Brooks(6), Danielle Moulia(6), Jennifer D. Loo(6), Maria Deloria Knoll(6), Daniel E. Park(6)